CRBU Q3 EPS Estimate Lifted by Brookline Capital Management

Key Points

• Brookline Capital Management raised its Q3 2025 EPS estimate for Caribou Biosciences to ($0.36) from ($0.38), reflecting improved expectations for the company's financial performance.
• Caribou Biosciences reported a Q3 EPS of ($0.35), exceeding the consensus estimate of ($0.40) and generating revenue of $2.67 million, significantly higher than the expected $1.64 million.
• Institutional investors hold 77.51% of Caribou Biosciences' shares, indicating strong backing from hedge funds and investment firms in the company's potential.

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Investment analysts at Brookline Capital Management boosted their Q3 2025 earnings per share estimates for Caribou Biosciences in a research note issued on Tuesday, August 12th. Brookline Capital Management analyst L. Cann now anticipates that the company will earn ($0.36) per share for the quarter, up from their previous estimate of ($0.38). The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share. Brookline Capital Management also issued estimates for Caribou Biosciences' Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.97) EPS, FY2027 earnings at ($1.41) EPS and FY2028 earnings at $2.02 EPS.

Several other brokerages also recently commented on CRBU. Wall Street Zen downgraded Caribou Biosciences from a "hold" rating to a "sell" rating in a report on Saturday. HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price objective (down previously from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $6.67.

Caribou Biosciences Stock Down 5.3%

NASDAQ CRBU traded down $0.10 on Friday, hitting $1.77. The stock had a trading volume of 889,965 shares, compared to its average volume of 1,348,443. Caribou Biosciences has a one year low of $0.66 and a one year high of $2.9995. The stock has a market cap of $164.82 million, a price-to-earnings ratio of -0.99 and a beta of 2.55. The company's 50-day moving average is $1.68 and its two-hundred day moving average is $1.25.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.05. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%.The firm had revenue of $2.67 million during the quarter, compared to analysts' expectations of $1.64 million.

Institutional Trading of Caribou Biosciences

A number of hedge funds have recently modified their holdings of CRBU. Hudson Bay Capital Management LP acquired a new stake in Caribou Biosciences in the 2nd quarter worth about $30,000. Tower Research Capital LLC TRC increased its position in Caribou Biosciences by 577.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 74,053 shares of the company's stock worth $93,000 after purchasing an additional 63,129 shares in the last quarter. Bridgeway Capital Management LLC increased its position in Caribou Biosciences by 36.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 148,500 shares of the company's stock worth $187,000 after purchasing an additional 40,000 shares in the last quarter. Brevan Howard Capital Management LP acquired a new position in Caribou Biosciences in the 2nd quarter valued at approximately $196,000. Finally, Jane Street Group LLC raised its position in Caribou Biosciences by 64.7% during the 2nd quarter. Jane Street Group LLC now owns 483,610 shares of the company's stock worth $609,000 after purchasing an additional 189,923 shares during the last quarter. Institutional investors and hedge funds own 77.51% of the company's stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.